Campath
Hi Cheri,
If you look at the links in Greg's post you will see that the trials are for patients with low risk MDS. You know I have seen still higher response rates (83 %) in patients treated with Vidaza and histone deacetylase inhibitors.
Kind regards
Birgitta-A
|